₹204.78
−6.09%NSE close, 16 Nov 2026
−18.75%
Godavari Biorefineries is a small cap company, listed on NSE under the symbol GODAVARIB. At ₹204.78 a share, the market values the whole company at ₹1,048 crore.
In FY26, it reported sales of ₹1,988 crore and a net profit of ₹4 crore, an operating margin of 6.4%.
The market values the company at 39.4 times its profit over the last twelve months and 1.39 times its book value; its return on equity is 3.5% and its borrowings are 0.72 times its equity.
Promoters hold 63.31% of the shares. Foreign institutions hold 0.22%, and domestic institutions, mutual funds among them, 9.96%.
Over the past year the share price has fallen 21.0%, and it is 42.0% below its 52-week high.
₹ crore. Consolidated figures.
Transcript
Link of Recording
Press Release for the Quarter and Half Year ended 30th September, 2026
| Sep 2026 |
|---|
| Sales | 321 | 447 | 580 | 533 | 431 | 460 | 564 | 558 | 549 |
|---|---|---|---|---|---|---|---|---|---|
| Expenses | 354 | 411 | 467 | 527 | 439 | 417 | 478 | 557 | 539 |
| Operating profit | −32.6 | 36.1 | 112 | 5.8 | −7.9 | 43.1 | 86.2 | 0.5 | 10.3 |
| Operating margin | -10.2% | 8.1% | 19.4% | 1.1% | -1.8% | 9.4% | 15.3% | 0.1% | 1.9% |
| Other income | 1.1 | 3.6 | 9.3 | 0.7 | 3.5 | 2.1 | 5.9 | 2.1 | 0.5 |
| Interest | 20.3 | 18.9 | 13.1 | 15.3 | 12.3 | 10.2 | 11.3 | 13.9 | 15.4 |
| Depreciation | 12.3 | 12.3 | 12.8 | 13.5 | 13.5 | 13.6 | 13.9 | 14.5 | 15.2 |
| Profit before tax | −64.1 | 8.5 | 95.7 | −22.3 | −56.9 | 13.5 | 70.3 | −25.9 | −19.8 |
| Tax | 10.9 | 2.7 | 23.8 | −6.3 | −15.3 | 5.2 | 17.4 | −6.5 | −4.5 |
| Net profit | −75.0 | 5.8 | 71.9 | −16.0 | −41.6 | 8.3 | 52.9 | −19.3 | −15.2 |
| EPS (₹) | -17.88 | 1.31 | 14.05 | -3.13 | -8.13 | 1.61 | 10.33 | -3.78 | -2.98 |
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 6.2 | 171 | 66.4 |
| From investing | −68.8 | −163 | −53.0 |
| From financing | 63.7 | −5.7 | −12.8 |
| Spent on fixed assets | −71.3 | −169 | −53.9 |
| Free cash flow | −65.1 | 2.4 | 12.4 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | -1.3% | 0.2% |
| Operating margin | 5.5% | 6.4% |
| Return on equity | -3.0% | 0.4% |
| Return on capital employed | 5.5% | 4.1% |
| Return on assets | -1.2% | 0.2% |
| Debt to equity | 0.63 | 0.67 |
| Interest coverage | 1.00 | 1.10 |
| Debt to assets | 0.25 | 0.26 |
| Current ratio | 1.16 | 1.13 |
| Quick ratio | 0.32 | 0.25 |
| Cash ratio | 0.01 | 0.02 |
| Asset turnover | 0.96 | 0.97 |
| Fixed asset turnover | 2.17 | 2.30 |
| Inventory turnover | 1.90 | 1.80 |
| Receivables turnover | 13.50 | 17.50 |
| Gross margin | 25.9% | 28.2% |
| Cash from operations to profit | – | 4,854.0% |
| Effective tax rate | – | 22.8% |
The financial results for the period ended September 30, 2026.
Schedule of meet
General Updates a United States-based patent application, entitled "5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER", has been granted
General Updates-- The Mexican Patent Office has granted our patent application entitled "USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS
A copy Srutinizers report of Annual General Meeting held on September 28, 2026. Further, the company has informed the Exchange regarding voting results.
Appointment of Mr Appointment/re-appointment of Directors.
Proceedings of Annual General Meeting held on September 28, 2026
Has informed regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Schedule of meet
General Updates Chinese Patent Office has granted our patent application entitled "USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS
General updates. that The European Patent Office has granted a patent application; Title: A Biofiller for Rubber Reinforcement